Resource Type

Journal Article 3

Year

2023 1

2021 1

Keywords

HMGCS2 1

SIRT 1

SIRT5 1

airway inflammation 1

anti-CTLA-4 1

anti-PD-1 1

bronchial hyperresponsiveness 1

immune checkpoint blockade 1

ketogenesis 1

liver-directed therapy 1

p65 1

particulate matter 2.5 1

sirtuin 2 1

sodium butyrate 1

succinylation 1

triptolide 1

uveal melanoma 1

open ︾

Search scope:

排序： Display mode:

Sodium butyrate activates HMGCS2 to promote ketone body production through SIRT5-mediated desuccinylation

Frontiers of Medicine 2023, Volume 17, Issue 2,   Pages 339-351 doi: 10.1007/s11684-022-0943-0

Abstract: The SB effect was significantly reduced by a SIRT5 inhibitor and in Sirt5-KO mice.The data suggests that SB activated HMGCS2 through SIRT5-mediated desuccinylation for ketone body production

Keywords： sodium butyrate     succinylation     HMGCS2     ketogenesis     SIRT5    

HTML PDF Collect

matter 2.5 triggers airway inflammation and bronchial hyperresponsiveness in mice by activating the SIRT2

Frontiers of Medicine 2021, Volume 15, Issue 5,   Pages 750-766 doi: 10.1007/s11684-021-0839-4

Abstract: Sirtuin 2 (SIRT2) is a key modulator in inflammation.However, the function and specific mechanisms of SIRT2 in PM2.5-induced airway inflammation are largelyTherefore, this work investigated the mechanisms of SIRT2 in regulating the phosphorylation and acetylationResults revealed that PM2.5 exposure lowered the expression and activity of SIRT2 in bronchial tissuesSubsequently, SIRT2 impairment promoted the phosphorylation and acetylation of p65 and activated the

Keywords： particulate matter 2.5     sirtuin 2     p65     airway inflammation     bronchial hyperresponsiveness     triptolide    

HTML PDF Collect

Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial

Frontiers of Medicine   Pages 878-888 doi: 10.1007/s11684-023-0993-y

Abstract: Metastases of uveal melanoma (UM) spread predominantly to the liver. Due to low response rates to systemic therapies, liver-directed therapies (LDT) are commonly used for tumor control. The impact of LDT on the response to systemic treatment is unknown. A total of 182 patients with metastatic UM treated with immune checkpoint blockade (ICB) were included in this analysis. Patients were recruited from prospective skin cancer centers and the German national skin cancer registry (ADOReg) of the German Dermatologic Cooperative Oncology Group (DeCOG). Two cohorts were compared: patients with LDT (cohort A, n = 78) versus those without LDT (cohort B, n = 104). Data were analyzed for response to treatment, progression-free survival (PFS), and overall survival (OS). The median OS was significantly longer in cohort A than in cohort B (20.1 vs. 13.8 months; P = 0.0016) and a trend towards improved PFS was observed for cohort A (3.0 vs. 2.5 months; P = 0.054). The objective response rate to any ICB (16.7% vs. 3.8%, P = 0.0073) and combined ICB (14.1% vs. 4.5%, P = 0.017) was more favorable in cohort A. Our data suggest that the combination of LDT with ICB may be associated with a survival benefit and higher treatment response to ICB in patients with metastatic UM.

Keywords： uveal melanoma     liver-directed therapy     immune checkpoint blockade     SIRT     anti-PD-1     anti-CTLA-4    

HTML PDF Collect

Title Author Date Type Operation

Sodium butyrate activates HMGCS2 to promote ketone body production through SIRT5-mediated desuccinylation

Journal Article

matter 2.5 triggers airway inflammation and bronchial hyperresponsiveness in mice by activating the SIRT2

Journal Article

Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial

Journal Article